Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial

Weber MA, Schmieder R, Kandzari DE, Townsend RR, Mahfoud F, Tsioufis K, Kario K, Pocock S, Tatakis F, Ewen S, Choi JW, East C, Lee DP, Ma A, Cohen DL, Wilensky R, Devireddy CM, Lea JP, Schmid A, Fahy M, Boehm M (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Clinical Research in Cardiology Springer Verlag (Germany)

DOI: 10.1007/s00392-022-02064-5

Abstract

The SPYRAL HTN-OFF MED Pivotal trial (https://clinicaltrials.gov/ct2/show/NCT02439749) demonstrated significant reductions in blood pressure (BP) after renal denervation (RDN) compared to sham control in the absence of anti-hypertensive medications. Prior to the 3-month primary endpoint, medications were immediately reinstated for patients who met escape criteria defined as office systolic BP (SBP) >= 180 mmHg or other safety concerns. Our objective was to compare the rate of hypertensive urgencies in RDN vs. sham control patients. Patients were enrolled with office SBP >= 150 and < 180 mmHg, office diastolic BP (DBP) >= 90 mmHg and mean 24 h SBP >= 140 and < 170 mmHg. Patients had been required to discontinue any anti-hypertensive medications and were randomized 1:1 to RDN or sham control. In this post-hoc analysis, cumulative incidence curves with Kaplan-Meier estimates of rate of patients meeting escape criteria were generated for RDN and sham control patients. There were 16 RDN (9.6%) and 28 sham control patients (17.0%) who met escape criteria between baseline and 3 months. There was a significantly higher rate of sham control patients meeting escape criteria compared to RDN for all escape patients (p = 0.032), as well as for patients with a hypertensive urgency with office SBP >= 180 mmHg (p = 0.046). Rate of escape was similar between RDN and sham control for patients without a measured BP exceeding 180 mmHg (p = 0.32). In the SPYRAL HTN-OFF MED Pivotal trial, RDN patients were less likely to experience hypertensive urgencies that required immediate use of anti-hypertensive medications compared to sham control.

Authors with CRIS profile

Roland Schmieder Professur für Innere Medizin (Nephrologie) Axel Schmid Institute of Radiology

Involved external institutions

Medtronic US United States (USA) (US) Jichi Medical University / 自治医科大学 JP Japan (JP) National and Kapodistrian University of Athens GR Greece (GR) Stanford University US United States (USA) (US) Baylor Jack and Jane Hamilton Heart and Vascular Hospital US United States (USA) (US) Emory University US United States (USA) (US) University of Pennsylvania US United States (USA) (US) London School of Hygiene and Tropical Medicine GB United Kingdom (GB) Piedmont Healthcare US United States (USA) (US) Universität des Saarlandes (UdS) DE Germany (DE) State University of New York at Albany (UNY Albany / UAlbany) US United States (USA) (US)

How to cite

APA:

Weber, M.A., Schmieder, R., Kandzari, D.E., Townsend, R.R., Mahfoud, F., Tsioufis, K.,... Boehm, M. (2022). Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-022-02064-5

MLA:

Weber, Michael A., et al. "Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial." Clinical Research in Cardiology (2022).

BibTeX: Download